Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

Table 2 LRG registry 3L+ regorafenib use compared to GRID trial

	No. of Pts/treatments	> 3rd line %	Median OS (months)	Median PFS/srPFS (months)
Phase III GRID Trial (regorafenib arm only)	133	44	17.4³²	4.8^a
LRG Registry 3L+	107/109^b	48.6	22.5	7.2

^a7.4 investigator assessment
^bTwo patients received two separate treatments of regorafenib beyond 2L for a total of 109 separate treatments beyond 2L. Four other patients received regorafenib 2L for a total of 113 treatments with single-agent regorafenib in the registry. Two of the 2L patients were intolerant to regorafenib. Four other patients received regorafenib in combination with another treatment. A total of 114 patients received 117 treatments with regorafenib when all treatment lines, single agent and combinations were included

ISSN: 2045-3329